Long-term outcome of everolimus treatment in transplant patients

References

• Meier-Kriesche HU, Schold HD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4: 378–383.
   PubMed Web of Science ®Google Scholar
• Gjertson DW. Survival trends in long-term first cadaver-donor kidney transplants. Clin Transpl. 1991:225–235.
   Google Scholar
• Meier-Kriesche HU, Schold JS, Kaplan B. Long term renal allograft survival: Have we made a significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4: 1289–1295.
   Google Scholar
• Nankivell BJ, Burrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–2333.
   PubMedGoogle Scholar
• Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation. 2002;74:1725–1734.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Grinyò J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The Caesar study. Am J Transplant. 2007;7: 560–570.
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007; 356:2271–2281.
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. mTOR signalling in growth and metabolism. Cell. 2006;124:471–484.
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369–391.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83–95.
   PubMed Web of Science ®Google Scholar
• MacDonald AS. Use of mTOR inhibitors in human organ transplantation. Exper Rev Clin Immunol. 2007;3:423–436.
   PubMedGoogle Scholar
• Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69: 48–56.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kaplan B, Tedesco Silva H, et al. Pharmacokinetics of an everolimus-cyclosporine regimen over the first 6 months after kidney transplantation. Am J Transplant. 2003;3:606–613.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: Pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant. 2003;22: 1117–1125.
   PubMed Web of Science ®Google Scholar
• Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol. 1999;48:694–703.
   PubMed Web of Science ®Google Scholar
• Budde K, Neumayer HH, Lehne G, et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant. 2004;19:2606–2614.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Figuiredo J, et al. Effect of food on everolimus absorption: Quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002 ;22 : 154–159.
   Google Scholar
• Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine. J Pharmacol Exp Ther. 2000;294:323–332.
   PubMed Web of Science ®Google Scholar
• Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit. 2002;24:53–58.
   PubMed Web of Science ®Google Scholar
• Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD: A new rapamycin derivative, synergy with cyclosporine. Transplantation. 1997;64: 32–35.
   PubMed Web of Science ®Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD: A new rapamycin derivative, pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36–42.
   PubMed Web of Science ®Google Scholar
• Hausen B, Gummert J, Berry GJ, et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000;69:76–86.
   PubMed Web of Science ®Google Scholar
• Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open label study. Transplantation. 2004;78:1332–1340.
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004;78:1532–1540.
   PubMed Web of Science ®Google Scholar
• Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5:2521–2530.
   PubMed Web of Science ®Google Scholar
• Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus myco-phenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005;80:244–252.
   PubMed Web of Science ®Google Scholar
• Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4:626–635.
   PubMed Web of Science ®Google Scholar
• Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation. 2009;88:1194–1202.
   PubMed Web of Science ®Google Scholar
• Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet. 2011;377:837–847.
   PubMed Web of Science ®Google Scholar
• Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant. 2005;19:145–152.
   PubMed Web of Science ®Google Scholar
• Sanchez-Fructuoso AI. Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2008;4;807–818.
   Web of Science ®Google Scholar
• Pascual J. The use of everolimus in renal-transplant patients. Int J NephrolRenovasc Dis. 2009;2:9–21.
   Google Scholar
• Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal transplant recipients. Am J Transplant. 2010;10:1–13.
   Google Scholar
• Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. J Nephrol. January 14, 2011. [Epub ahead of print].
   Web of Science ®Google Scholar
• Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008;85:821–826.
   PubMed Web of Science ®Google Scholar
• Pascual J, del Castillo D, Cabello M, et al. Interaction between everolimus and tacrolimus in renal transplant recipients: A pharmacokinetic controlled trial. Transplantation. 2010;89:994–1000.
   PubMed Web of Science ®Google Scholar
• Tedesco-Silva H Jr, Rosso Felipe C, de Sandes Freitas TV, Pontello Cristeli M, Araùjo Rodrigues C, Medina Pestana JO. Impact of everolimus: Update on immunosuppressive therapy strategies and patient outcomes after renal transplantation. Transplant Research and Risk Management. 2011;3:9–29.
   Google Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDV RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36–42.
   PubMed Web of Science ®Google Scholar
• Smith MS, Bentz GL, Smith PM, Bivins ER, Yurochko AD. HCMV activates PI(3)K in monocytes and promotes monocyte motility and trans-endothelial migration in a PI(3)K-dependent manner. J Leukoc Biol. 2004;76:65–76.
   PubMed Web of Science ®Google Scholar
• Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation – challenging the status quo. Clin Transplant. 2007;21:149–158.
   PubMed Web of Science ®Google Scholar
• Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581–589.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebocontrolled phase III trial. Lancet. 2008;372:449–456.
   PubMed Web of Science ®Google Scholar
• Yau JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low and intermediate grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol. 2008;26: 4311–4318.
   Web of Science ®Google Scholar
• Treiber G. mTOR inhibitors for hepatocellular cancer: A forward-moving target. Expert Rev Anticancer Ther. 2009;9:246–261.
   Web of Science ®Google Scholar
• Gabardi S, Baroletti S. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology and cardiology. Pharmacotherapy. 2010;30:1044–1056.
   PubMed Web of Science ®Google Scholar
• Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol. 2004;15:228–233.
   PubMed Web of Science ®Google Scholar
• Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation. 2009;88:69–76.
   PubMed Web of Science ®Google Scholar
• Letavernier E, Legendre C. mTOR inhibitors-induced proteinuria: Mechanisms significance and management. Transplant Rev. 2008;22: 125–130.
   Google Scholar
• Franz S, Tregeniter A, Hopfer H, Mihatsch M, Dickermann N. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: An ancillary study from a randomized controlled trial. Am J Kidney Dis. 2010;55:335–343.
   PubMed Web of Science ®Google Scholar
• Bertoni E, Bruschi M, Candiano G, et al. Post-transplant proteinuria associated with everolimus. Transplant Proc. 2009;41:216–217.
   Web of Science ®Google Scholar
• Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth-factor stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995;59:390–395.
   PubMed Web of Science ®Google Scholar
• Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold-ischemia induced vascular remodeling. Transplant Proc. 1999;31:390–395.
   Web of Science ®Google Scholar
• Neumayer HH. Introducing everolimus (Certican. in organ transplantation: An overview of preclinical and early clinical developments. Transplantation. 2005;79(9 Suppl):S72–S75.
   PubMed Web of Science ®Google Scholar
• Delgado JF, Manito N, Segovia J, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando). 2009;23:69–79.
   PubMedGoogle Scholar
• Shimohama T, Ako J, Yamasaki M, et al. SPIRIT III JAPAN versus SPIRIT III USA: A comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol. 2010;106:13–17.
   Web of Science ®Google Scholar
• Eisen HJ, Murat Tuzcu E, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–858.
   PubMed Web of Science ®Google Scholar
• Vigano M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: A 24-month analysis. J Heart Lung Transplant. 2007;26:584–592.
   PubMed Web of Science ®Google Scholar
• Lehmkuhl HB, Arizon J, Viganò M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation. 2009;88:115–122.
   PubMed Web of Science ®Google Scholar